Aldeyra Therapeutics
ALDX
26 hedge funds and large institutions have $34.7M invested in Aldeyra Therapeutics in 2017 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 5 closing their positions.
40% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 5
14% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 7
8% more funds holding
Funds holding: 24 → 26 (+2)
3.08% less ownership
Funds ownership: 52.23% → 49.16% (-3.1%)
39% less capital inflows, than outflows
Capital inflows: $4.11M | Capital outflows: $6.71M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
+$2.41M |
| 2 |
Sphera Funds Management
Tel Aviv,
Israel
|
+$954K |
| 3 |
Hikari Power
Tokyo,
Japan
|
+$323K |
| 4 |
Renaissance Technologies
New York
|
+$133K |
| 5 |
Virtu KCG Holdings
New York
|
+$103K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIC
AWM Investment Company
New York
|
-$4.56M |
| 2 |
Boxer Capital
San Diego,
California
|
-$1.46M |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$377K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$235K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$39K |
ALDX Hedge Fund Activity: Q2 2017 in Review
26 of the 4,023 institutional investors tracked by Wall St. Rank reported a position in Aldeyra Therapeutics (ALDX) for Q2 2017, worth a combined $34.7M — down 8.5% from $38M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new ALDX positions and 5 closed out — a net gain of 2 holders — while 8 added to existing stakes and 7 trimmed.
The largest buyer was 683 Capital Management, opening a new position worth an estimated $2.41M. The largest seller was AWM Investment Company, exiting entirely with an estimated $4.56M sold.
- 26 institutional investors held Aldeyra Therapeutics (ALDX) as of Q2 2017, up from 24 in Q1 2017.
- Funds reported $34.7M of Aldeyra Therapeutics stock for Q2 2017, down 8.5% quarter-over-quarter.
- 7 funds opened new Aldeyra Therapeutics positions in Q2 2017 and 5 closed out, a net change of +2 holders.
- The largest Aldeyra Therapeutics buyer in Q2 2017 was 683 Capital Management, an estimated $2.41M added.
- The largest Aldeyra Therapeutics seller in Q2 2017 was AWM Investment Company, an estimated $4.56M sold.
Based on aggregated 13F filings for Q2 2017.